A detailed history of Exane Derivatives transactions in Dbv Technologies S.A. stock. As of the latest transaction made, Exane Derivatives holds 101 shares of DBVT stock, worth $68. This represents 0.0% of its overall portfolio holdings.

Number of Shares
101
Previous 101 -0.0%
Holding current value
$68
Previous $0 NaN%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2021

Apr 30, 2021

SELL
$2.75 - $6.57 $5,222 - $12,476
-1,899 Reduced 94.95%
101 $0
Q4 2020

Jan 27, 2021

BUY
$1.38 - $3.01 $1,606 - $3,503
1,164 Added 139.23%
2,000 $5,000
Q3 2020

Oct 06, 2020

SELL
$1.58 - $4.77 $19,219 - $58,022
-12,164 Reduced 93.57%
836 $1,000
Q1 2020

Apr 17, 2020

BUY
$2.33 - $12.98 $30,290 - $168,740
13,000 New
13,000 $50,000

Others Institutions Holding DBVT

About DBV Technologies S.A.


  • Ticker DBVT
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 187,776,992
  • Market Cap $128M
  • Description
  • DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products. Its lead product candidate is Viaskin Peanut, an immunotherapy product, which has completed Phase III clinical trial for the treatment of peanut allergies in 4 to 11 years of age children, adolescents...
More about DBVT
Track This Portfolio

Track Exane Derivatives Portfolio

Follow Exane Derivatives and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Exane Derivatives, based on Form 13F filings with the SEC.

News

Stay updated on Exane Derivatives with notifications on news.